Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
NCT03482752Phase 3Terminated
- Sponsor
- Savara
- Start
- Apr 2018
- Primary completion
- Jan 2021
- Modality
- Cytokines & Interferons
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Primary endpoints: Number of Treatment-emergent Adverse Events at 139 weeks, Number of Serious Treatment-emergent Adverse Events at 139 weeks and 2 more. Started Apr 2018; status: terminated.
02
Drugs
molgramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT03482752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482752.